Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Van Linden A, Blumenstein J, Walther T, et al. (2013) . Clinical research in cardiology : official journal of the German Cardiac Society 102:241-243
Transcatheter aortic valve implantation (T-AVI) has emerged as a standardized routine procedure to treat elderly high-risk patients suffering from severe aortic valve stenosis and the number of worldwide implantations is increasing [2-4]. The two mostly common used approaches are transapical (TA)  and transfemoral (TF)  using the Edwards SAPIEN (XT)™ and the Medtronic CoreValve® prostheses. Meanwhile several “second generation” T-AVI prostheses have entered the market either for TA or TF approach. Two CE-mark approved TA devices are the Symetis ACURATE TA™ and the JenaValve™. Both are porcine valves on a self-expandable nitinol stent with unique stepwise implantation features [7, 8]. After gaining more experience with T-AVI in native stenotic valves, the idea of implanting a T-AVI prosthesis in degenerated xenografts has been developed and also emerged to an alternative treatment option [9-15]. Furthermore, immediately valve-in-valve implantation of a second T-AVI prosthesis in a failed T-AVI prosthesis has turned out to be a rescue option to avoid sternotomy and conversion to conventional aortic valve replacement .Our case report describes the first valve-in-valve implantations of an Edwards SAPIEN XT™ prosthesis in second generation T-AVI prostheses using the TA approach . In both cases a severe aortic regurgitation >2+ indicated immediate treatment. Re-ballooning did not reduce the regurgitation and the decision for rescue valve-in-valve implantation was made. Both procedures could be performed successfully without any complications. Both patients were alive at 1-year follow up with NYHA functional class I and echocardiography showed excellent hemodynamic function of the prostheses (mean gradients ≤10 mmHg).In summary, valve-in-valve implantation of a SAPIEN (XT)™ prosthesis inside an ACURATE TA™ or a JenaValve™ prosthesis seems to be an adequate rescue option for severe aortic regurgitation after implantation of these second generation T-AVI prostheses.
This letter reports 2 complicated transapical TAVI cases using new-generation self-expanding prostheses. In both cases, malpositioning of the prosthesis caused severe paraprosthetic aortic regurgitation, requiring a rescue valve-in-valve implantation using a SAPIEN transcatheter valve, with a good final result and a favorable one-year outcome. This report may invite 2 comments.
© 2017 European Society of Cardiology. All rights reserved